Literature DB >> 11771997

Effect of ErbB2 coexpression on the kinetic interactions of epidermal growth factor with its receptor in intact cells.

John C Wilkinson1, James V Staros.   

Abstract

We have extended the use of stopped-flow mixing and fluorescence anisotropy detection to investigate in real-time the effects of ErbB2 coexpression on the kinetic interactions of epidermal growth factor (EGF) with the EGF receptor. Using stable 32D-derived cell lines expressing both the EGF receptor and ErbB2, and fluorescein-labeled H22Y murine EGF (F-EGF), a series of association and dissociation experiments were performed in which the kinetic interaction of F-EGF with cells was monitored by observing time-dependent changes in fluorescence anisotropy following rapid mixing. Data were collected at various concentrations of F-EGF and multiple cell densities, using cells that express similar levels of the EGF receptor but different levels of ErbB2, and then analyzed by fitting to a two independent receptor-class model using global analysis techniques. The recovered kinetic parameters indicated that the coexpression of ErbB2 had relatively modest effects on recovered rate constants and calculated K(d) values, but a significant effect on the fraction of receptors associated with the high-affinity receptor class. This effect on the fraction of high-affinity receptors depended on the relative expression of ErbB2, as higher ErbB2 expression levels correlated with a larger fraction of high-affinity receptors. Further, the increase in the fraction of high-affinity receptors due to the presence of ErbB2 occurred without any change in the total number of EGF binding sites per cell. Thus, we have identified modulation of the relative populations of high- and low-affinity classes of EGF receptors as a consequence of coexpression of ErbB2 with the EGF receptor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11771997     DOI: 10.1021/bi015839l

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  4 in total

1.  Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies.

Authors:  Nadège Gaborit; Christel Larbouret; Julie Vallaghe; Frédéric Peyrusson; Caroline Bascoul-Mollevi; Evelyne Crapez; David Azria; Thierry Chardès; Marie-Alix Poul; Gérard Mathis; Hervé Bazin; André Pèlegrin
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

2.  Investigation of the dimerization of proteins from the epidermal growth factor receptor family by single wavelength fluorescence cross-correlation spectroscopy.

Authors:  Ping Liu; Thankiah Sudhaharan; Rosita M L Koh; Ling C Hwang; Sohail Ahmed; Ichiro N Maruyama; Thorsten Wohland
Journal:  Biophys J       Date:  2007-04-27       Impact factor: 4.033

3.  In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.

Authors:  Christel Larbouret; Nadège Gaborit; Thierry Chardès; Mickaël Coelho; Emmanuelle Campigna; Caroline Bascoul-Mollevi; Jean-Pierre Mach; David Azria; Bruno Robert; André Pèlegrin
Journal:  Neoplasia       Date:  2012-02       Impact factor: 5.715

4.  Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A.

Authors:  Soheila Kazemi; Shinsaku Kawaguchi; Christian E Badr; Daphne R Mattos; Ana Ruiz-Saenz; Jeffrey D Serrill; Mark M Moasser; Brian P Dolan; Ville O Paavilainen; Shinya Oishi; Kerry L McPhail; Jane E Ishmael
Journal:  Biochem Pharmacol       Date:  2020-11-03       Impact factor: 5.858

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.